NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $0.97 +0.01 (+1.04%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.93▼$1.0050-Day Range$0.79▼$1.1452-Week Range$0.62▼$1.95Volume1.67 million shsAverage Volume1.64 million shsMarket Capitalization$120.94 millionP/E RatioN/ADividend YieldN/APrice Target$4.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Karyopharm Therapeutics alerts: Email Address Karyopharm Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside374.0% Upside$4.60 Price TargetShort InterestBearish15.16% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.97Based on 3 Articles This WeekInsider TradingSelling Shares$1.24 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.16) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector176th out of 930 stocksPharmaceutical Preparations Industry76th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Karyopharm Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.16% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 12.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 2.8 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,235,527.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.16) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Karyopharm Therapeutics Stock (NASDAQ:KPTI)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPTI Stock News HeadlinesJuly 26 at 4:52 AM | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average of $1.11July 18, 2024 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200-Day Moving Average of $1.11July 28, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 15, 2024 | insidermonkey.comKaryopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?July 5, 2024 | prnewswire.comXPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the CountryJuly 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2024 | prnewswire.comAntengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South KoreaJune 3, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 28, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 1, 2024 | prnewswire.comKaryopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesMay 29, 2024 | prnewswire.comKaryopharm to Participate at the Jefferies Global Healthcare ConferenceMay 23, 2024 | investorplace.comThe Next Novavax? 3 Biopharma Stocks to Buy Before They BoomMay 10, 2024 | seekingalpha.comKPTI Karyopharm Therapeutics Inc.May 10, 2024 | markets.businessinsider.comBuy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic OutlookMay 10, 2024 | finance.yahoo.comKaryopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | markets.businessinsider.comOptimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical TrialsMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...See More Headlines Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/28/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$4.60 High Stock Price Target$7.00 Low Stock Price Target$3.00 Potential Upside/Downside+374.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,100,000.00 Net Margins-104.18% Pretax Margin-103.94% Return on EquityN/A Return on Assets-57.80% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.99 Sales & Book Value Annual Sales$146.03 million Price / Sales0.83 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-0.82Miscellaneous Outstanding Shares124,620,000Free Float119,258,000Market Cap$120.94 million OptionableOptionable Beta0.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 57)President, CEO & Director Comp: $1.43MMs. Sohanya Cheng M.B.A. (Age 41)Executive VP & Chief Commercial Officer Comp: $742.95kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Reshma Rangwala M.D. (Age 46)Ph.D., Executive VP, Chief Medical Officer & Head of Research Comp: $777.32kDr. Mansoor Raza Mirza M.D. (Age 63)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Comp: $150kDr. Sharon Shacham M.B.A. (Age 54)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Comp: $1.4MMr. Cameron Peters (Age 64)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. Michael J. Mano J.D. (Age 47)Senior VP, General Counsel & Secretary Comp: $625.08kMr. James Accumanno J.D.Chief Compliance OfficerMore ExecutivesKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAIAltimmuneNASDAQ:ALTOculisNASDAQ:OCSEditas MedicineNASDAQ:EDITTourmaline BioNASDAQ:TRMLView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 320,745 shares on 7/26/2024Ownership: 0.133%Richard A PaulsonSold 3,616 sharesTotal: $3,073.60 ($0.85/share)Deepika PakianathanSold 231,548 sharesTotal: $219,970.60 ($0.95/share)Deepika PakianathanSold 468,044 sharesTotal: $449,322.24 ($0.96/share)Richard A PaulsonSold 3,592 sharesTotal: $3,556.08 ($0.99/share)View All Insider TransactionsView All Institutional Transactions KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $0.8650 at the beginning of the year. Since then, KPTI stock has increased by 12.2% and is now trading at $0.9705. View the best growth stocks for 2024 here. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $33.13 million for the quarter, compared to the consensus estimate of $35.02 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. Who are Karyopharm Therapeutics' major shareholders? Top institutional investors of Karyopharm Therapeutics include Bank of New York Mellon Corp (0.13%). Insiders that own company stock include Richard A Paulson, Michael Mason, Reshma Rangwala, Michael Mano, Sohanya Roshan Cheng, Stuart Poulton, Stephen Mitchener, Garen G Bohlin, Deepika Pakianathan, Sharon Shacham, Jatin Shah and Michael Kauffman. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA) and Advanced Micro Devices (AMD). This page (NASDAQ:KPTI) was last updated on 7/28/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.